Shoreline Biosciences raises $43M to advance allogenic NK and macrophage cell therapies

April 7, 2021

Shoreline Biosciences Inc., a San Diego-based company developing allogenic natural killer and macrophage cellular therapies for cancer and other diseases, has raised $43 million in a financing led by Boxer Capital.

BioWorld Newco news Cancer Cell therapy

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for April 9.

Somalogic to merge with CM Life Sciences II SPAC, as trendy IPO path continues

BioWorld MedTech

Somalogic Inc. has agreed to go public via a merger with blank-check company CM Life Sciences II. Upon closing, CMLS II – a special purpose acquisition company...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for April 9.

Global cases rise, but more weapons advance to combat COVID-19

BioWorld

As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.